Aria Diagnostics Raises $52.7M to Commercialize Non-Invasive Trisomy Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Aria Diagnostics said today that it has raised $52.7 million in Series C funding that it will use to commercialize a prenatal test to detect fetal aneuploidies such as trisomy 21.

New investors include Meritech Capital Partners and an undisclosed mutual fund group. Existing investors Venrock and Domain Associates also participated in the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.